Value through InnovationSeptember 14 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease


New analysis showed dose adjustment of Gilotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer


New Long-Term Data Demonstrates Continued Safety and Beneficial Effect of Ofev® (Nintedanib) for Patients with IPF


Tiotropium RESPIMAT® Improved Lung Function with Safety Comparable to Placebo in Children with Asthma


Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment


New Data: STIOLTO® RESPIMAT® (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD


Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE® immuno-oncology drug for multiple myeloma


Qualcomm and Boehringer Ingelheim Pharmaceuticals collaborate to add new digital technology to RESPIMAT® inhaler


ESC Congress 2016 Late Breaking Science Registry: Latest Data on Pradaxa (dabigatran etexilate mesylate) Safety and Effectiveness Profile Show Low Rates of Bleeding and Stroke in NVAF Patients in Routine Clinical Care


Boehringer Ingelheim and Duke Clinical Research Institute Expand Collaboration to Create Largest Patient Registry for Idiopathic Pulmonary Fibrosis (IPF)

back 1 2 3 4 5 6 7 8 9 10